Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Jan-Feb;7(1):10-5.
doi: 10.1310/0B0R-J1LP-KQPF-43HB.

Clinically stable treatment-experienced adults receiving tenofovir and didanosine

Antonio Di Biagio  1 , Andrea Beltrame, Giovanni Cenderello, Giuseppe Ferrea, Andrea De Maria
Affiliations
Clinical Trial

Clinically stable treatment-experienced adults receiving tenofovir and didanosine

Antonio Di Biagio et al. HIV Clin Trials. 2006 Jan-Feb.

Abstract

Method: Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine.

Results: Patients treated with TDF and ddI do not have a higher risk of early immunological or virological failure.

Conclusion: Treatment success and increase in CD4+ lymphocytes may depend, among other factors, on historical CD4+ nadir. These data agree with previous work and argue against preemptive switches for fear of side effects or immunological/virological failure away from a successful ddI-TDF combination in clinically stable drug-experienced patients.

PubMed Disclaimer

Publication types